Grace Therapeutics (GRCE) & Its Competitors Financial Analysis

Grace Therapeutics (NASDAQ:GRCE) is one of 1,072 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Grace Therapeutics to similar companies based on the strength of its profitability, dividends, earnings, institutional ownership, risk, analyst recommendations and valuation.

Earnings & Valuation

This table compares Grace Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grace Therapeutics	N/A	-$12.85 million	-1.67
Grace Therapeutics Competitors	$9.89 billion	$136.37 million	-5.58

Grace Therapeutics’ competitors have higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Grace Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	0	0	1	0	3.00
Grace Therapeutics Competitors	8443	22305	50503	1353	2.54

Grace Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 518.56%. As a group, “Pharmaceutical preparations” companies have a potential upside of 256.12%. Given Grace Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Grace Therapeutics is more favorable than its competitors.

Risk and Volatility

Grace Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Grace Therapeutics’ competitors have a beta of 3.84, meaning that their average share price is 284% more volatile than the S&P 500.

Insider & Institutional Ownership

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.5% of Grace Therapeutics shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Grace Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-20.10%	-17.10%
Grace Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Summary

Grace Therapeutics beats its competitors on 7 of the 13 factors compared.

Grace Therapeutics Company Profile

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.